These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29025245)

  • 1. Hepatic chemerin mRNA in morbidly obese patients with nonalcoholic fatty liver disease.
    Kajor M; Kukla M; Waluga M; Liszka Ł; Dyaczyński M; Kowalski G; Żądło D; Berdowska A; Chapuła M; Kostrząb-Zdebel A; Bułdak RJ; Sawczyn T; Hartleb M
    Pol J Pathol; 2017; 68(2):117-127. PubMed ID: 29025245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaspin mRNA levels in the liver of morbidly obese women with nonalcoholic fatty liver disease.
    Waluga M; Kukla M; Żorniak M; Grabiec M; Kajor M; Dyaczyński M; Kowalski G; Żądło D; Berdowska A; Kotulski R; Bułdak RJ; Sawczyn T; Waluga E; Olczyk P; Hartleb M
    Pol J Pathol; 2017; 68(2):128-137. PubMed ID: 29025246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease.
    Döcke S; Lock JF; Birkenfeld AL; Hoppe S; Lieske S; Rieger A; Raschzok N; Sauer IM; Florian S; Osterhoff MA; Heller R; Herrmann K; Lindenmüller S; Horn P; Bauer M; Weickert MO; Neuhaus P; Stockmann M; Möhlig M; Pfeiffer AF; von Loeffelholz C
    Eur J Endocrinol; 2013 Nov; 169(5):547-57. PubMed ID: 23935128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor-21 and omentin-1 hepatic mRNA expression and serum levels in morbidly obese women with non-alcoholic fatty liver disease.
    Waluga M; Kukla M; Zorniak M; Kajor M; Liszka L; Dyaczynski M; Kowalski G; Zadlo D; Waluga E; Olczyk P; Buldak RJ; Berdowska A; Hartleb M
    J Physiol Pharmacol; 2017 Jun; 68(3):363-374. PubMed ID: 28820393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis.
    Pohl R; Haberl EM; Rein-Fischboeck L; Zimny S; Neumann M; Aslanidis C; Schacherer D; Krautbauer S; Eisinger K; Weiss TS; Buechler C
    Eur J Clin Invest; 2017 Jan; 47(1):7-18. PubMed ID: 27797398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic chemerin and chemokine-like receptor 1 expression in patients with chronic hepatitis C.
    Kukla M; Adamek B; Waluga M; Zalewska-Ziob M; Kasperczyk J; Gabriel A; Mazur W; Sobala-Szczygieł B; Bułdak RJ; Zajęcki W; Kępa L; Ziora K; Żwirska-Korczala K; Wiczkowski A; Hartleb M
    Biomed Res Int; 2014; 2014():517820. PubMed ID: 25121101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity.
    Bekaert M; Ouwens DM; Hörbelt T; Van de Velde F; Fahlbusch P; Herzfeld de Wiza D; Van Nieuwenhove Y; Calders P; Praet M; Hoorens A; Geerts A; Verhelst X; Kaufman JM; Lapauw B
    Obesity (Silver Spring); 2016 Dec; 24(12):2544-2552. PubMed ID: 27768254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemerin in a Mouse Model of Non-alcoholic Steatohepatitis and Hepatocarcinogenesis.
    Haberl EM; Pohl R; Rein-Fischboeck L; Feder S; Sinal CJ; Buechler C
    Anticancer Res; 2018 May; 38(5):2649-2657. PubMed ID: 29715085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemerin/CMKLR1 ameliorates nonalcoholic steatohepatitis by promoting autophagy and alleviating oxidative stress through the JAK2-STAT3 pathway.
    An X; Liu J; Li Y; Dou Z; Li N; Suo Y; Ma Y; Sun M; Tian Z; Xu L
    Peptides; 2021 Jan; 135():170422. PubMed ID: 33144092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery.
    Sell H; Divoux A; Poitou C; Basdevant A; Bouillot JL; Bedossa P; Tordjman J; Eckel J; Clément K
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2892-6. PubMed ID: 20375212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SFRP5 hepatic expression is associated with non-alcoholic liver disease in morbidly obese women.
    Gutiérrez-Vidal R; Vega-Badillo J; Reyes-Fermín LM; Hernández-Pérez HA; Sánchez-Muñoz F; López-Álvarez GS; Larrieta-Carrasco E; Fernández-Silva I; Méndez-Sánchez N; Tovar AR; Villamil-Ramírez H; Mejía-Domínguez AM; Villarreal-Molina T; Hernández-Pando R; Campos-Pérez F; Aguilar-Salinas CA; Canizales-Quinteros S
    Ann Hepatol; 2015; 14(5):666-74. PubMed ID: 26256895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemerin is highly expressed in hepatocytes and is induced in non-alcoholic steatohepatitis liver.
    Krautbauer S; Wanninger J; Eisinger K; Hader Y; Beck M; Kopp A; Schmid A; Weiss TS; Dorn C; Buechler C
    Exp Mol Pathol; 2013 Oct; 95(2):199-205. PubMed ID: 23906870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The expression of chemerin and the influence of sitagliptin on its expression in non-alcoholic fatty liver disease rats complicated with prediabetes].
    Zhang L; Gao XF; Wang YH
    Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(30):2407-2413. PubMed ID: 30138985
    [No Abstract]   [Full Text] [Related]  

  • 15. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum chemerin and vaspin in non-alcoholic fatty liver disease.
    Kukla M; Zwirska-Korczala K; Hartleb M; Waluga M; Chwist A; Kajor M; Ciupinska-Kajor M; Berdowska A; Wozniak-Grygiel E; Buldak R
    Scand J Gastroenterol; 2010; 45(2):235-42. PubMed ID: 20095887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemokine-Like Receptor 1 mRNA Weakly Correlates with Non-Alcoholic Steatohepatitis Score in Male but Not Female Individuals.
    Neumann M; Meier EM; Rein-Fischboeck L; Krautbauer S; Eisinger K; Aslanidis C; Pohl R; Weiss TS; Buechler C
    Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27548138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deregulation of Secreted Frizzled-Related Protein 5 in Nonalcoholic Fatty Liver Disease Associated with Obesity.
    Bertran L; Portillo-Carrasquer M; Aguilar C; Porras JA; Riesco D; Martínez S; Vives M; Sabench F; Gonzalez E; Del Castillo D; Richart C; Auguet T
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34198988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis.
    Hohenester S; Christiansen S; Nagel J; Wimmer R; Artmann R; Denk G; Bischoff M; Bischoff G; Rust C
    Am J Physiol Gastrointest Liver Physiol; 2018 Sep; 315(3):G329-G338. PubMed ID: 29878845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemokine-like receptor 1 deficiency does not affect the development of insulin resistance and nonalcoholic fatty liver disease in mice.
    Gruben N; Aparicio Vergara M; Kloosterhuis NJ; van der Molen H; Stoelwinder S; Youssef S; de Bruin A; Delsing DJ; Kuivenhoven JA; van de Sluis B; Hofker MH; Koonen DP
    PLoS One; 2014; 9(4):e96345. PubMed ID: 24781986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.